HCPCS Level II
J1939
Injection, bumetanide, 0.5 mg
Codes near J1939
These sit next to J1939 in the CMS Level II file. All J codes
- J1921Injection, labetalol hydrochloride (hikma), not therapeutically equivalent to j1920, 5 mg
- J1930Injection, lanreotide, 1 mg
- J1931Injection, laronidase, 0.1 mg
- J1932Injection, lanreotide, (cipla), 1 mg
- J1938Injection, furosemide, 1 mg
- J1940Injection, furosemide, up to 20 mg
- J1941Injection, furosemide (furoscix), 20 mg
- J1942Injection, aripiprazole lauroxil, 1 mg
- J1943Injection, aripiprazole lauroxil, (aristada initio), 1 mg
- J1944Injection, aripiprazole lauroxil, (aristada), 1 mg
NDC crosswalk
| NDC | Drug | Labeler | Billable units |
|---|---|---|---|
| 00641-6007-10 | Bumetanide | Hikma Pharmaceuticals USA Inc. | 50 |
| 00641-6008-10 | Bumetanide | Hikma Pharmaceuticals USA Inc. | 20 |
| 00641-6161-10 | Bumetanide | Hikma Pharmaceuticals USA Inc. | 20 |
| 00641-6162-10 | Bumetanide | Hikma Pharmaceuticals USA Inc. | 50 |
| 00641-6284-10 | Bumetanide | Hikma Pharmaceuticals USA Inc. | 20 |
| 00641-6285-10 | Bumetanide | Hikma Pharmaceuticals USA Inc. | 50 |
| 25021-0321-04 | Bumetanide | Sagent Pharmaceuticals | 20 |
| 25021-0321-10 | Bumetanide | Sagent Pharmaceuticals | 50 |
| 65219-0570-04 | Bumetanide | FreseniUS Kabi USA, LLC | 20 |
| 65219-0572-10 | Bumetanide | FreseniUS Kabi USA, LLC | 50 |
| 68462-0469-54 | Bumetanide | Glenmark Pharmaceuticals Inc., USA | 20 |
| 68462-0470-54 | Bumetanide | Glenmark Pharmaceuticals Inc., USA | 50 |
| 70748-0323-10 | Bumetanide | Lupin Pharmaceuticals, Inc. | 20 |
| 70748-0323-11 | Bumetanide | Lupin Pharmaceuticals, Inc. | 50 |
| 70860-0406-10 | Bumetanide | Athenex Pharmaceutical Division, LLC | 50 |
| 72205-0101-07 | Bumetanide | Novadoz Pharmaceuticals LLC | 20 |
| 72205-0102-07 | Bumetanide | Novadoz Pharmaceuticals LLC | 50 |
| 72572-0040-10 | Bumetanide | Civica, Inc. | 20 |
| 72572-0041-10 | Bumetanide | Civica, Inc. | 50 |
| 83301-0080-02 | Bumetanide | Mullan Pharmaceutical Inc. | 20 |
| 83301-0081-02 | Bumetanide | Mullan Pharmaceutical Inc. | 50 |
Source: CMS ASP NDC-HCPCS crosswalk, effective October 1, 2026 through December 31, 2026.